Understanding the Role of Tech Transfer CDMOs in Biologics Manufacturing
- Technology transfer is the controlled translation of process knowledge, analytical methods, and manufacturing instructions from an innovator to a qualified CDMO.
- In biologics manufacturing, an effective tech transfer CDMO program protects product quality, process consistency, and GMP compliance while enabling reliable scale-up from laboratory to clinical or commercial production.
Tech Transfer CDMOs in Biologics Manufacturing Scope and Responsibilities
Tech transfer to CDMO acts as the receiving organization responsible for converting a development-scale biological process into a reproducible manufacturing operation. The scope of technology transfer in biologics commonly includes the process development: upstream cell culture, harvest and clarification, downstream purification, formulation, bulk drug substance manufacturing, analytical testing and stability studies. Main objective is to preserve the scientific intent and quality performance of the process under different equipment, facility, and operating conditions.
Biologics process transfer must account for scale-dependent phenomena that may not be significant during laboratory development. Changes in equipment or CDMO operation can alter cellular metabolism and process performance. Before tech transfer CDMO must identify these differences before GMP manufacturing begins and determine whether they require process adaptation, additional characterization, or formal comparability studies. Successful biologics manufacturing transfer is demonstrated by consistent product quality and predictable process performance.1
The responsibilities of the innovator and the biologics CDMO should be clearly allocated through the master services agreement, statement of work, quality agreement, responsibility matrix, and technology-transfer plan.
| Innovator | CDMO |
| Development history | Facility suitability assessment |
| Process descriptions | Technical gaps identification |
| Raw material specifications | Transfer protocols preparation |
| Cell bank information | Quality systems qualification |
| Analytical panel description | Personnel training |
| Reference standards | Manufacturing documentation adoption |
| Known process sensitivities | Execution of engineering batches |
| Track record of previous deviations | Execution of GMP-compliant batches |
Innovator is generally responsible for providing the development history, process descriptions, executed development records, analytical methods, reference standards, cell-bank information, raw-material specifications, stability knowledge, previous deviations, known process sensitivities, and relevant regulatory commitments. The CDMO is responsible for evaluating facility and equipment fit, identifying technical gaps, preparing transfer protocols, qualifying systems, training personnel, adapting manufacturing documentation, executing engineering and GMP batches, and documenting the conclusions of the transfer.
Both parties share responsibility for change control, risk acceptance, comparability planning, deviation management, milestone approval, and regulatory communication.
Key Stages of Tech Transfer in Biopharmaceutical Development
Technology transfer begins with project initiation and technical due diligence. The joint project team defines the transfer objective, target scale, intended clinical or commercial use, decision rights, and technical workstreams. The innovator provides the available process development and manufacturing information for multidisciplinary assessment. The tech transfer CDMO compares the process requirements with its facility, quality systems and manufacturing capacity. This stage concludes with an approved transfer plan, preliminary risk register, responsibility matrix, quality agreement, schedule, deliverables, and technical acceptance criteria.
The second stage integrates knowledge transfer, analytical-method transfer, and remediation of identified gaps. Explicit knowledge is transferred through controlled documents, while tacit process knowledge is captured through workshops, process walk-throughs, interviews with subject-matter experts, site visits, and observation of laboratory operations. Each unit operation is mapped to receiving-site equipment, with attention to differences in working volume, operating principle, control logic, instrumentation, and disposable assemblies. Analytical procedures are transferred through predefined protocols covering instruments, reagents, reference standards, sample preparation, system suitability, precision, accuracy, and interlaboratory equivalence. Any unresolved difference is converted into a controlled action involving material bridging, equipment modification, analytical redevelopment, additional process characterization, or revision of the proposed operating ranges.2
The third stage focuses on biologics scale-up and transfer through process characterization and engineering verification. Representative scale-down models, risk-based experiments, and engineering batches are used to determine whether the receiving process maintains performance within predefined ranges. The results are evaluated through yield, mass balance, impurity clearance, process-intermediate quality, and the critical quality attributes (CQAs) of the biological product.
The final stage of a tech transfer CDMO project comprises GMP implementation, manufacturing confirmation, comparability assessment, and formal transfer closure. The accepted process is translated into master batch records, standard operating procedures, sampling plans, analytical worksheets, material specifications, and electronic recipes. Equipment qualification, material availability and operator qualification are confirmed before GMP production begins. The GMP batch is evaluated against predefined criteria for selected parameters.3
The technology transfer is closed through an approved report. This document records deviations, process changes, conclusions regarding comparability, residual risk, monitoring requirements, and the formal transfer to routine GMP production of biological drugs.
Knowledge Transfer and Documentation in Tech Transfer CDMO Programs
Knowledge transfer in biologics programs involves both explicit and tacit forms of process understanding.
| Explicit knowledge | Tacit knowledge |
| Process parameters | Visual process endpoints |
| Specifications | Sampling nuances |
| Critical quality attributes | Order of additions |
| Analytical panel description | Equipment behavior |
| Acceptance criteria | Bioreactor foam patterns |
| Raw material attributes | Filtration characteristics |
| Development results | Timing of operator interventions |
Transferring documents without direct interaction between the sending and receiving teams is insufficient for a complex biological process. Effective knowledge transfer requires structured collaboration among scientists from different departments. Workshops, live demonstrations, batch record reviews, question logs, historical data reviews, and joint risk assessments allow the receiving CDMO to understand not only how the process is performed but also why each control is required.
Tech transfer documentation is routinely prepared by both the innovator and the CDMO. The innovator’s documentation package should include:
- Process description
- Flow diagrams
- Process development history
- Quality Target Product Profile (QTPP)
- CQA assessments
- Critical process parameter evaluations
- Control strategy
- Cell bank records
- Equipment requirements
- Analytical procedures
- Reference standards
- Regulatory commitments
The CDMO subsequently generates its own controlled transfer documentation, including:
- Due-diligence report
- Transfer risk assessment
- Technology transfer protocol
- Analytical transfer protocols
- Equipment equivalency evaluations
- Scale-up reports
- Master batch records
- Standard operating procedures
- Engineering batch reports
- GMP batch documentation
- Comparability assessments
- Final transfer report
Data integrity and change control pathways should be defined before execution begins. This documentation provides traceability from the original development process to the final receiving-site control strategy. It also supports regulatory inspection readiness.
Managing Process Consistency During Tech Transfer Activities
During the initial phase, corresponding approximately to the first two months, the receiving team assesses whether the laboratory process contains sufficient knowledge to support clinical-scale development. Then the process is compared with available manufacturing equipment and facility controls. A structured quality risk assessment connects potential scale-up failures with the Quality Target Product Profile, critical quality attributes, critical process parameters, and critical material attributes. The resulting development plan defines the process and method transfers and decision gates required before GMP manufacture.4
The next phase, typically covering months two to five in a ten-month tech transfer CDMO program, concentrates on scale translation and analytical readiness. Biologics scale-up is typically complex and tailored to the specific project. It requires bioprocessing optimization. Analytical transfer proceeds in parallel so that development and engineering samples can be evaluated.
During approximately months five to eight, an engineering demonstration integrates the complete process under conditions representative of the clinical-scale manufacturing facility. The production of engineering batches is preceded by the establishment of operating ranges, a sampling plan, and the master process schedule. Process data are compared with development-scale expectations to determine whether equipment or scale differences have introduced new gradients, bottlenecks, or sources of variability. When a difference is detected, the team evaluates its potential influence on critical quality attributes before changing feed delivery or process conditions. Any adjustment is documented through change control and supported by an appropriate scientific rationale. Additional experiments or a second engineering run may be necessary where the initial evidence does not provide sufficient assurance of process consistency.
The final phase of the tech transfer CDMO program, covering approximately months eight to ten, establishes GMP readiness and executes the clinical manufacturing batch. Manufacturing records, specifications, procedures, and equipment readiness are reviewed before batch initiation. The first GMP run is performed with enhanced technical oversight and predefined escalation rules for process excursions or unexpected analytical results. Unit-operation recovery and product CQAs are assessed against transfer acceptance criteria. Following satisfactory testing and quality review, the transfer report documents process performance, deviations, implemented changes, comparability conclusions, residual risks, and requirements for continued process verification.
| Threat to process integrity | Impact on the manufacturing process | Potential effect on CQAs or process parameters | Risk mitigation |
| Nonrepresentative scale-down model | Misleading development conclusions | Altered growth, yield, impurity clearance, or molecular heterogeneity | Scale-down model qualification against manufacturing scale or representative engineering data |
| Incomplete knowledge transfer | Unexplained deviations, unrecorded operating nuances, inconsistent execution | Viability, titer, glycosylation, charge variants, aggregation, potency, host-cell protein clearance, overall yield | Structured subject-matter-expert interviews, process walk-throughs, formal knowledge-gap assessments |
| Equipment mismatch | Alter mixing, mass transfer, shear, heat removal | Cell viability, productivity, PTMs | Engineering calculations and scientifically justified scale-up criteria |
| Contamination | Process safety, cross-contamination | Sterility-related attributes (purity, potency) | Mock runs, enhanced manufacturing-floor oversight, contamination control strategy |
| Analytical method transfer failure | Analytical bias | Potency, purity, aggregate content, charge variants, glycan profiles, impurities | Analytical transfer with an approved protocol with predefined equivalence criteria |
Regulatory and Quality Considerations in Tech Transfer CDMO Operations
The European Medicines Agency doesn’t regulate technology transfer as a separate, isolated approval procedure. Instead, the transfer is evaluated through the pharmaceutical quality system and GMP-compliance. ICH Q5E guideline provides the scientific framework for determining whether a biological product manufactured before and after a process change remains comparable, and ICH Q9(R1) supports science-based quality risk management.5,6 The EMA guideline on process validation for biotechnology-derived active substances addresses process characterization and verification data for marketing authorization applications and variations. For an authorized medicinal product, transfer to a new manufacturing site or implementation of a significant process change may also require a variation under Regulation (EC) No 1234/2008 and the revised Variations Guidelines applicable from 15 January 2026.
The FDA similarly evaluates tech transfer CDMO activities through applicable cGMP, Chemistry, Manufacturing, and Controls (CMC). The principal regulatory framework includes 21 CFR Parts 210 and 211 and the relevant provisions of 21 CFR Parts 600–680 for biological products. Process validation guidance applies a lifecycle model comprising process design, process qualification, and continued process verification, making transfer activities part of a broader state of manufacturing control. FDA guidance on contract manufacturing quality agreements recommends clearly assigning responsibility for manufacturing, while recognizing that a contract does not remove either party’s applicable cGMP obligations. For an approved Biologics License Application (BLA), 21 CFR 601.12 requires the applicant to inform FDA of changes to the product and production process. Regulatory reporting integral components of the transfer strategy.7
How Effective Tech Transfer Supports Reliable Biologics Manufacturing?
Effective technology transfer supports reliable biologics manufacturing by converting development knowledge into a controlled, executable, and traceable production process. Reliable technology transfer in biologics is demonstrated by reproducible process performance and consistent product quality.
By combining process science, analytical comparability, engineering knowledge, and GMP quality systems, Mabion can translate laboratory-scale innovation into controlled GMP biologics manufacturing for clinical and commercial production.
FAQ
Prepared by:
Marketing Specialist
References
- CDMO World. Biologics Tech Transfer to CDMOs: Risks and Best Practices. 2026.
- Kochanowski N, Malphettes L. Technology transfer and scale down model development strategy for biotherapeutics produced in mammalian cells. BMC Proc. 2013; 7(Suppl 6): P86.
- Raś A, Przywara M, Zapała W. Technology Transfer in the Pharmaceutical Industry within Regulatory Frameworks, Strategies and Implementation Practice. Chem. Technol. Biotechnol. 2026; 7: 259-266.
- Sampathkumar K, Kerwin BA. Roadmap for Drug Product Development and Manufacturing of Biologics. J Pharm Sci. 2024; 113(2): 314-331.
- European Medicines Agency. ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products. 2005.
- European Medicines Agency. ICH Q9 Quality risk management. 2023.
- Welch A. FDA Invents: How Technology Transfer Gets FDA Inventions from Lab to Marketplace. FDA Voice. 2024.
